Dicloxacillin‐warfarin drug–drug interaction—A register‐based study and in vitro investigations in 3D spheroid primary human hepatocytes

Dicloxacillin is used to treat staphylococcal infections and we have previously shown that dicloxacillin is an inducer of cytochrome P450 enzymes (CYPs). Here, we employed a translational approach to investigate the effect of a treatment with dicloxacillin on warfarin efficacy in Danish registries. Furthermore, we assessed dicloxacillin as an inducer of CYPs in vitro.

[1]  M. Ingelman-Sundberg,et al.  3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction , 2022, bioRxiv.

[2]  D. Ramsden,et al.  Characterization of Correction Factors to Enable Assessment of Clinical Risk from In Vitro CYP3A4 Induction Data and Basic Drug-Drug Interaction Models , 2022, European Journal of Drug Metabolism and Pharmacokinetics.

[3]  D. Stresser,et al.  Broad Application of CYP3A4 Liquid Chromatography-Mass Spectrometry Protein Quantification in Hepatocyte Cytochrome P450 Induction Assays Identifies Nonuniformity in mRNA and Protein Induction Responses , 2021, Drug Metabolism and Disposition.

[4]  T. Stage,et al.  Clinical and Molecular Perspectives on Inflammation‐Mediated Regulation of Drug Metabolism and Transport , 2021, Clinical pharmacology and therapeutics.

[5]  D. Stresser,et al.  Enrichment-free High-throughput Liquid Chromatography–Multiple-Reaction Monitoring Quantification of Cytochrome P450 Proteins in Plated Human Hepatocytes Direct from 96-Well Plates Enables Routine Protein Induction Measurements , 2020, Drug Metabolism and Disposition.

[6]  Sabine U. Vorrink,et al.  Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three‐Dimensional Spheroid Cultures of Primary Human Hepatocytes , 2020, Clinical pharmacology and therapeutics.

[7]  Dave L Dixon,et al.  Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.

[8]  P. B. Jensen,et al.  Ischemic Stroke and Systemic Embolism in Warfarin Users With Atrial Fibrillation or Heart Valve Replacement Exposed to Dicloxacillin or Flucloxacillin , 2020, Clinical pharmacology and therapeutics.

[9]  Christopher Southan,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes , 2019, British journal of pharmacology.

[10]  A. Pottegård,et al.  The Effect of Flucloxacillin on Warfarin Anticoagulation: A Swedish Register-Based Nationwide Cohort Study , 2019, Thrombosis and Haemostasis.

[11]  Xue Pan,et al.  A new similarity method for assessment of pharmacokinetic interaction between flucloxacillin and midazolam. , 2019, Pharmazie.

[12]  D. Tweedie,et al.  Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance , 2018, Drug Metabolism and Disposition.

[13]  P. Artursson,et al.  Direct Quantification of Cytochromes P450 and Drug Transporters—A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates , 2018, Drug Metabolism and Disposition.

[14]  A. Pottegård,et al.  Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro , 2018, British journal of clinical pharmacology.

[15]  F. Weiß,et al.  Concept: The Use of Targeted Immunoaffinity Proteomics for Routine Assessment of In Vitro Enzyme Induction. , 2017, Journal of pharmaceutical sciences.

[16]  D. Tweedie,et al.  Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control , 2017, Drug Metabolism and Disposition.

[17]  Benjamin Berger,et al.  Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail , 2016, Front. Pharmacol..

[18]  H. Sørensen,et al.  Data Resource Profile: The Danish National Prescription Registry , 2016, International journal of epidemiology.

[19]  Hongbing Wang,et al.  Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective , 2016, Drug Metabolism and Disposition.

[20]  M. Ingelman-Sundberg,et al.  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease , 2016, Scientific Reports.

[21]  A. Hassan,et al.  Warfarin‐drug interactions: An emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate , 2016, Journal of clinical pharmacology.

[22]  A. Pottegård,et al.  Change in International Normalized Ratio Among Patients Treated With Dicloxacillin and Vitamin K Antagonists. , 2015, JAMA.

[23]  Henrik Toft Sørensen,et al.  The Danish Civil Registration System as a tool in epidemiology , 2014, European Journal of Epidemiology.

[24]  L. Zhang,et al.  Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data , 2014, Clinical pharmacology and therapeutics.

[25]  Zhijun Wang,et al.  PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers , 2013, European Journal of Clinical Pharmacology.

[26]  N. Rizzo-Padoin,et al.  Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial. , 2011, British journal of clinical pharmacology.

[27]  G. Miller,et al.  Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. , 2010, Drug metabolism letters.

[28]  Sean Ekins,et al.  A Comprehensive in Vitro and in Silico Analysis of Antibiotics That Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine , 2008, Drug Metabolism and Disposition.

[29]  F. Penning-van Beest,et al.  Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants , 2007, Journal of thrombosis and haemostasis : JTH.

[30]  L. Benet,et al.  Effect of the MDR1 C3435T Variant and P‐Glycoprotein Induction on Dicloxacillin Pharmacokinetics , 2005, Journal of clinical pharmacology.

[31]  A. Wittkowsky.  Warfarin and Other Coumarin Derivatives: Pharmacokinetics, Pharmacodynamics, and Drug Interactions , 2003, Seminars in vascular medicine.

[32]  A. Hofman,et al.  Overanticoagulation Associated with Combined Use of Antibacterial Drugs and Acenocoumarol or Phenprocoumon Anticoagulants , 2002, Thrombosis and Haemostasis.

[33]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[34]  C. Sorkness,et al.  Potential Interaction between Warfarin and Dicloxacillin , 1996, The Annals of pharmacotherapy.

[35]  N. Frimodt-Møller,et al.  Dicloxacillin and flucloxacillin: Pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration , 1995, Infection.

[36]  Shino Kuramoto,et al.  Evaluation of Methods to Assess CYP3A Induction Risk in Clinical Practice Using in Vitro Induction Parameters. , 2021, Biological & pharmaceutical bulletin.

[37]  L. Herngren,et al.  Pharmacokinetics and distribution of flucloxacillin in pacemaker patients , 2004, European Journal of Clinical Pharmacology.

[38]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[39]  M. Barza.  Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 2: penicillins. , 1977, American journal of hospital pharmacy.

[40]  M. Barza,et al.  Pharmacokinetics of the Penicillins in Man , 1976, Clinical pharmacokinetics.